4.6 Article

Secondary malignancies and survival of FCR-treated patients with chronic lymphocytic leukemia in Central Europe

期刊

CANCER MEDICINE
卷 12, 期 2, 页码 1961-1971

出版社

WILEY
DOI: 10.1002/cam4.5033

关键词

CLL population; FCR therapy; secondary malignancy; survival

类别

向作者/读者索取更多资源

This study is the first to analyze a large sample of chronic lymphocytic leukemia (CLL) patients across multiple countries, aiming to evaluate the incidence, types, and key prognostic factors of secondary malignancies, as well as the impact on overall survival. The study analyzed data from 25,814 newly diagnosed CLL patients from Czechia, Hungary, and Poland, and observed that 33.7% of treated patients developed secondary malignancies during the study. The study concludes that secondary malignancies in CLL patients are an underestimated burden and deserve deeper considerations in decision making.
This is the first large-scale cross-country analysis of patients with chronic lymphocytic leukemia (CLL) aimed to evaluate the incidence, types, and key prognostic factors of secondary malignancies, and to assess the impact on overall survival based on retrospective claims data from three Central European countries. We analyzed 25,814 newly diagnosed CLL patients from Czechia, Hungary, and Poland; 10,312 (39.9%) patients were treated for CLL in study periods between 2004 and 2016. Out of the treated patients, 1986 (19.3%) received the FCR therapy in the first line and 779 (7.6%) received FCR in subsequent lines. We observed that 33.7% of treated patients developed secondary malignancies during the study. Based on country estimates, the probability to develop a secondary malignancy within 4 years since starting the first-line FCR therapy ranged between 28.0% and 36.8%. We found the age at diagnosis, male gender, any malignancy prior to the CLL diagnosis, and the CLL treatment to be the key risk factors for developing secondary malignancies. Specifically, the FCR therapy was a statistically significant (p < 0.001) prognostic factor for risk increase with the hazard ratio between 1.46 and 1.60. Across the three Central European countries, we observed consistent results indicating FCR increased the risk of secondary malignancies in CLL patients. We conclude that secondary malignancies are clearly an undervalued burden for CLL patients, caregivers, and the healthcare system. When evaluating new therapies in regulatory and reimbursement decision making, the factor of secondary malignancies deserves deeper considerations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据